ArticleJournal of thoracic disease2018

Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

David Crossman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.